Efficacy of FOLFOX+Bevacizumab in Combination With Irinotecan in the Treatment of Metastatic Colorectal Cancer (CHARTA)

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2014 by Martin-Luther-Universität Halle-Wittenberg
Sponsor:
Collaborator:
Roche Pharma AG
Information provided by (Responsible Party):
Hans-Joachim Schmoll, MD, Martin-Luther-Universität Halle-Wittenberg
ClinicalTrials.gov Identifier:
NCT01321957
First received: March 23, 2011
Last updated: May 20, 2014
Last verified: May 2014
  Purpose

The primary objective of this study is to evaluate the efficacy of Irinotecan in combination with FOLFOX+Bevacizumab versus FOLFOX+Bevacizumab alone in the first-line treatment of patients with metastatic colorectal cancer.


Condition Intervention Phase
Metastatic Colorectal Cancer
Drug: Oxaliplatin, 5FU/LV, Bevacizumab
Drug: 5FU/LV, Oxaliplatin, Bevacizumab, Irinotecan
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: FOLFOX and Bevacizumab With or Without Irinotecan in First-line Treatment for Metastatic Colorectal Cancer. A Randomized Phase II Study

Resource links provided by NLM:


Further study details as provided by Martin-Luther-Universität Halle-Wittenberg:

Primary Outcome Measures:
  • progression free survival rate [ Time Frame: 9 months after first study drug administration ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • tumour response according to RECIST v 1.1 [ Time Frame: until progression of disease for a maximum of two years after end of treatment ] [ Designated as safety issue: No ]
  • Secondary resection rate [ Time Frame: for a maximum of two years after end of treatment ] [ Designated as safety issue: No ]
  • Progression free survival rate [ Time Frame: until progression of disease for a maximum of two years after end of treatment ] [ Designated as safety issue: No ]
  • Overall survival [ Time Frame: until death for a maximum of two years after end of treatment ] [ Designated as safety issue: No ]
  • Adverse events [ Time Frame: 18 months after the date of last study drug administration ] [ Designated as safety issue: Yes ]
    Toxicity of study medication

  • Quality of life [ Time Frame: Until end of treatment (maximum 2 years after first study drug administration) ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 250
Study Start Date: May 2011
Estimated Study Completion Date: January 2017
Estimated Primary Completion Date: January 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: FOLFOX+Bevacizumab
bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/ m2 iv over 48 hours (day 1-3)
Drug: Oxaliplatin, 5FU/LV, Bevacizumab
bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/ m2 iv over 48 hours (day 1-3)
Other Names:
  • Bevacizumab
  • Oxaliplatin
  • I-LV
  • 5-FU
Experimental: FOLFOX+Bevacizumab+Irinotecan
bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) irinotecan at a dose of 165 mg/m2 iv over two hours (day 1) oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/ m2 iv over 48 hours (day 1-3)
Drug: 5FU/LV, Oxaliplatin, Bevacizumab, Irinotecan
bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) irinotecan at a dose of 165 mg/m2 iv over two hours (day 1) oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/ m2 iv over 48 hours (day 1-3)
Other Names:
  • Bevacizumab
  • Oxaliplatin
  • I-LV
  • 5-FU
  • Irinotecan

Detailed Description:

5-Fluorouracil and oxaliplatin (FOLFOX-Regimen) in combination with bevacizumab is regarded as standard first-line treatment in metastatic colorectal cancer [Saltz et al., 2008]. Current studies established the role of the FOLFOXIRI regimen [Souglakos et al., 2006, Falcone et al., 2007]. A further intensification of the therapy seems feasible yielding response rates up to 84% and a disease control rate up to 100% [Falcone, 2008, Santomaggio, 2009, Masi, 2010]. This trial evaluates the activity of an intensified first-line therapy for metastatic colorectal cancer compared to standard treatment.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Patients with histologically confirmed diagnosis of stage IV (UICC) colorectal cancer (primary tumor may be present)
  2. Patients with at least one measurable lesion, with size > 1 cm (RECIST v1.1)
  3. ECOG Performance status ≤ 2 (ECOG 2, only if tumor related)
  4. Patients, who are able to tolerate intensive first lien treatment as judged by the investigator
  5. Life expectancy > 3 months
  6. Age ≥ 18 years
  7. Haematologic function: ANC ≥ 1.5 x 109/L, platelets ≥ 100 x109/L, hemoglobin

    • 9 g/dl or 5.59 mmol/l
  8. Patients not receiving therapeutic anticoagulation must have an INR < 1.5 ULN and aPTT < 1.5 ULN within 7 days prior to registration. The use of full dose anticoagulants is allowed as long as the INR or aPTT is within therapeutic limits (according to the medical standard in the institution) and the patient has been on a stable dose for anticoagulants for at least two weeks at the time of registration.
  9. Adequate liver function as measured by serum transaminases (AST & ALT) ≤ 2.5 x ULN (in case of liver metastases < 5 x ULN) and total bilirubin ≤ 1.5 x ULN
  10. Adequate renal function: Serum creatinine ≤ 1.5 x ULN
  11. Signed, written informed consent

Exclusion Criteria:

  1. Patients with histologically confirmed diagnosis of stage IV (UICC) colorectal cancer (primary tumor may be present)
  2. Patients with at least one measurable lesion, with size > 1 cm (RECIST v1.1)
  3. ECOG Performance status ≤ 2 (ECOG 2, only if tumor related)
  4. Patients, who are able to tolerate intensive first lien treatment as judged by the investigator
  5. Life expectancy > 3 months
  6. Age ≥ 18 years
  7. Haematologic function: ANC ≥ 1.5 x 109/L, platelets ≥ 100 x109/L, hemoglobin

    • 9 g/dl or 5.59 mmol/l
  8. Patients not receiving therapeutic anticoagulation must have an INR < 1.5 ULN and aPTT < 1.5 ULN within 7 days prior to registration. The use of full dose anticoagulants is allowed as long as the INR or aPTT is within therapeutic limits (according to the medical standard in the institution) and the patient has been on a stable dose for anticoagulants for at least two weeks at the time of registration.
  9. Adequate liver function as measured by serum transaminases (AST & ALT) ≤ 2.5 x ULN (in case of liver metastases < 5 x ULN) and total bilirubin ≤ 1.5 x ULN
  10. Adequate renal function: Serum creatinine ≤ 1.5 x ULN
  11. Signed, written informed consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01321957

Contacts
Contact: KKS Halle +49 345 557 4908 Aio0209@kks-halle.de

  Show 51 Study Locations
Sponsors and Collaborators
Martin-Luther-Universität Halle-Wittenberg
Roche Pharma AG
Investigators
Principal Investigator: Hans-Joachim Schmoll, MD Universitätsklinikum Halle
  More Information

No publications provided by Martin-Luther-Universität Halle-Wittenberg

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Hans-Joachim Schmoll, MD, MD, Martin-Luther-Universität Halle-Wittenberg
ClinicalTrials.gov Identifier: NCT01321957     History of Changes
Other Study ID Numbers: AIO-0209
Study First Received: March 23, 2011
Last Updated: May 20, 2014
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Additional relevant MeSH terms:
Colorectal Neoplasms
Colonic Diseases
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Intestinal Diseases
Intestinal Neoplasms
Neoplasms
Neoplasms by Site
Rectal Diseases
Bevacizumab
Camptothecin
Irinotecan
Oxaliplatin
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Enzyme Inhibitors
Growth Inhibitors
Growth Substances
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Radiation-Sensitizing Agents
Therapeutic Uses
Topoisomerase I Inhibitors
Topoisomerase Inhibitors

ClinicalTrials.gov processed this record on October 21, 2014